Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 ,inter alia, to consider and approve take on record ....
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has informed the stock exchanges that its Board of Directors will meet on Monday, 9th February 2026. The key agenda item is to consider, approve, and take on record the unaudited financial results for the third quarter and nine months ended 31st December 2025. The filing was made under Regulations 29 and 33 of the LODR, which is the standard procedure for listed companies before announcing quarterly results. No financial figures, guidance, or other business items are disclosed in this intimation.
This is a routine regulatory disclosure with no direct impact on shareholders or stock price. Investors should watch for the actual Q3 results announcement on or after 9th February 2026, which will contain the performance numbers.